Monitoring for cytomegalovirus after stem cell transplant
Part of Immune system & allergy, Infections clinical trials.
This study looks at how well a new blood test detects cytomegalovirus (a common virus) in people who have had a stem cell transplant. The test may help doctors catch the virus early and treat it faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to have a stem cell transplant using cells from a donor (allogeneic transplant).
- You are able to give blood samples for the study.
- You are not pregnant or breastfeeding.
- You are an adult and can understand the study procedures.
- You do not have other serious health conditions that would make study participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This study tracks how well ganciclovir (an antiviral medicine) works in transplant recipients who develop a resistant CMV infection. Researchers will review medical records to understand treatment success and patient outcomes.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.